Cempra Inc (CEMP) 9.67 $CEMP
Treatments for Non-Alcoholic Steatohepatitis Making Clinical Strides
ACCESSWIRE - Tue Apr 08, 10:00AM CDT
WHITEFISH, MT / April 8, 2014 / There has been a disease steadily filling market headlines recently, and no; it's not cancer. It's fatty liver disease, particularly Non-alcoholic Fatty Liver Disease, or NAFLD, regarded by many as the most common non-communicable liver disease worldwide. The disease is a silent killer that often goes undetected until late stages, for which there are no FDA-approved treatments. Biotechs focusing on innovative therapies for varying stages of NAFLD are receiving plenty of deserved media coverage. Hepatology leaders in recent headlines include Intercept Pharmaceuticals, (NASDAQ: ICPT), Cempra, Inc. (NASDAQ: CEMP), MediciNova, Inc. (NASDAQ: MNOV), Galectin Therapeutics (NASDAQ: GALT) and Lumena Pharmaceuticals, a company preparing to go public.
Cempra's Solithromycin Demonstrates Therapeutic Potential Beyond Anti-Bacterial Activity
GlobeNewswire - Thu Apr 03, 3:05PM CDT
Cempra, Inc. (Nasdaq:CEMP) today announced the presentation of a late-breaking abstract entitled "Anti-NASH Effects of Solithromycin in NASH-HCC Mouse Model," at 9:15 a.m. EDT, May 6, at Digestive Disease Week (DDW(R)) 2014 in Room S105A at McCormick Place in Chicago. The presentation will be included in the session entitled "Basic Late Breaking Abstract Session."
Tetraphase Antibiotic Nearing Key Tolerability Test
at The Street - Wed Apr 02, 7:00AM CDT
The lead-in phase of a phase III study will tell us a lot about whether Tetraphase's eravacycline antibiotic can be administered orally.
Cempra to Present Late-Breaker on Solithromycin Reducing Inflammation in an Animal Model for Cancer Chemotherapy-Induced Lung Injury
GlobeNewswire - Thu Mar 27, 7:14AM CDT
Study Suggests Clinical Uses of Solithromycin Beyond Bacterial Infections
Cempra, Inc. to Present at The 21st Annual Future Leaders in the Biotech Industry Conference and Needham & Co. 12th Annual Healthcare Conference
GlobeNewswire - Thu Mar 20, 3:12PM CDT
Cempra, Inc. (Nasdaq:CEMP) today announced that Prabhavathi Fernandes, Ph.D., chief executive officer of Cempra, will present at The 21 Annual Future Leaders in the Biotech Industry Conference at 11:30 a.m. EDT, Friday, March 28, at the Millennium Broadway Hotel & Conference Center in New York City and at the Needham & Co. 12 Annual Healthcare Conference at 12:50 p.m. EDT, Wednesday, April 9, at The Westin New York Grand Central in New York City. Dr. Fernandes will discuss the company's two differentiated antibiotics, solithromycin (CEM-101) for community-acquired bacterial pneumonia and TAKSTA (CEM-102 or fusidic acid) for the chronic, oral treatment of Gram-positive pathogens including methicillin-resistant S. aureus (MRSA) in prosthetic joint infections.
What Falling Estimates & Price Mean for Cempra (CEMP) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 14, 7:45AM CDT
Cempra has witnessed a significant price decline in the past four weeks. The reason is negative trend in earnings estimate revisions. The stock also has seen some pretty dismal trading lately.
Cempra, Inc. to Present at Barclays Capital 2014 Global Healthcare Conference and 26th Annual ROTH Conference
GlobeNewswire - Fri Mar 07, 2:58AM CST
Cempra, Inc. (Nasdaq:CEMP) today announced that Prabhavathi Fernandes, Ph.D., chief executive officer of Cempra, will present at the Barclays Capital 2014 Global Healthcare Conference at 3:45 p.m. EST, Wednesday, March 12, at the Loews Miami Hotel in Miami Beach, Fla. and at the 26 Annual ROTH Conference at 3:30 p.m. PST, Monday, March 10, at The Ritz Carlton in Laguna Niguel, Calif. Dr. Fernandes will discuss the company's two differentiated antibiotics, solithromycin (CEM-101) for community-acquired bacterial pneumonia and TAKSTA (CEM-102 or fusidic acid) for the chronic, oral treatment of Gram-positive pathogens including methicillin-resistant S. aureus (MRSA) in prosthetic joint infections.
Cempra (CEMP) Falls: Stock Plunges 12.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 03, 7:35AM CST
The shares of Cempra fell over 12% on the day. This breaks the recent trend of the company, as the stock is now trading within the volatile price range of $11.2 to $13.7 in the past one-month time frame. This pharmaceutical company has seen a flat track record when it comes to current year estimate revisions.
Nasdaq stocks posting largest percentage decreases
AP - Fri Feb 28, 5:03PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Cempra, Inc. Reports Fourth Quarter and Full Year 2013 Financial and Operating Results
GlobeNewswire - Thu Feb 27, 3:14PM CST
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today reported financial results for the fourth quarter and full year ended Dec. 31, 2013. The company will host a conference call and webcast at 4:30 p.m. EST, today.
Report Reveals Wide Gap Between Successful and Struggling Communities, Reshaping American Landscape
PR Newswire - Wed Feb 26, 7:30AM CST
According to a comprehensive new report, there is a startling contrast in economic prosperity between successful and struggling American communities. America is divided into nine different community profiles, ranging from the successful -- the "Affluent Metroburbs" -- to the genuinely troubled -- the "Endangered Communities." Fifty percent of the American communities studied are struggling to find their way forward after the Great Recession.
Diabetic Gastroparesis - Pipeline Review, H1 2014 Research Report
M2 - Mon Feb 24, 3:19AM CST
Research and Markets (http://www.researchandmarkets.com/research/7ctztm/diabetic) has announced the addition of the "Diabetic Gastroparesis - Pipeline Review, H1 2014" report to their offering. 'Diabetic Gastroparesis - Pipeline Review, H1 2014', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Diabetic Gastroparesis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Diabetic Gastroparesis. Scope - A snapshot of the global therapeutic scenario for Diabetic Gastroparesis. - A review of the Diabetic Gastroparesis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Diabetic Gastroparesis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction Diabetic Gastroparesis Overview Therapeutics Development Late Stage Products Clinical Stage Products Early Stage Products Unknown Stage Products Assessment by Monotherapy Products Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Assessment by Therapeutic Class Drug Profiles metoclopramide hydrochloride - Drug Profile RM-131 - Drug Profile velusetrag - Drug Profile Non-Antibiotic Macrolide Program for Gastric Disorders - Drug Profile TC-6499 - Drug Profile Featured News & Press Releases Appendix List of Tables List of Figures Companies Mentioned Theravance, Inc. Evoke Pharma, Inc. Targacept, Inc. Cempra, Inc. Rhythm Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/7ctztm/diabetic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Cempra (CEMP) Jumps: Stock Adds 6.1% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 21, 8:39AM CST
Cempra, Inc. was a big mover last session, as its shares rose just over 6% on the day.
Cempra, Inc. to Report Fourth Quarter and Full Year 2013 Financial and Operating Results, and Host Conference Call and Webcast on Feb. 27, 2014
GlobeNewswire - Thu Feb 20, 3:20PM CST
Cempra, Inc. (Nasdaq:CEMP) today announced that it will report fourth quarter and full year 2013 financial results and provide a business update after the close of U.S. financial markets on Feb. 27, 2014. Prabhavathi Fernandes, Ph.D., president and chief executive officer of Cempra will host a conference call and webcast at 4:30 p.m. EST, Feb. 27, 2014.
Cempra Initiates Solithromycin Pediatric Program
GlobeNewswire - Thu Feb 20, 6:00AM CST
Cempra, Inc. (Nasdaq:CEMP) today announced the dosing of the first patient in its Phase 1 study of solithromycin capsules in children. The clinical trial is funded through Cempra's contract with the Biomedical Advanced Research and Development Authority (BARDA; http://www.phe.gov/about/barda/Pages/default.aspx).
Cempra, Inc. to Present at RBC Capital Markets 2014 Global Healthcare Conference and Cowen 34th Annual Health Care Conference
GlobeNewswire - Wed Feb 19, 3:05PM CST
Cempra, Inc. (Nasdaq:CEMP) today announced that Prabhavathi Fernandes, Ph.D., chief executive officer of Cempra, will present at the RBC Capital Markets 2014 Global Healthcare Conference at 1:35 p.m. EST, Tuesday, Feb. 25, at The New York Palace Hotel in New York City, and at the Cowen 34 Annual Health Care Conference at 1:30 p.m. EST, Monday, March 3, at The Boston Marriott Copley Place in Boston. Dr. Fernandes will discuss the company's two differentiated antibiotics, solithromycin (CEM-101) for community-acquired bacterial pneumonia and TAKSTA (CEM-102 or fusidic acid) for the chronic, oral treatment of Gram-positive pathogens including methicillin-resistant S. aureus (MRSA) in prosthetic joint infections.
Cempra (CEMP) Catches Eye: Stock Rises 9.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 12, 8:46AM CST
Cempra was a big mover last session, with shares rising nearly 10%.
Sensors Market in Consumer Electronics by Product, Application, & Geography - Worldwide Market Forecasts and Analysis to 2020
PR Newswire - Wed Feb 12, 6:22AM CST
Research and Markets
Cempra Antibiotic Candidate Clears Important Heart Safety Hurdle
at The Street - Tue Feb 11, 10:29AM CST
Cempra's solithromycin may have an important safety advantage over competing compounds.
Treatments for Non-Alcoholic Steatohepatitis Making Clinical Strides
ACCESSWIRE - Tue Apr 08, 10:00AM CDT
WHITEFISH, MT / April 8, 2014 / There has been a disease steadily filling market headlines recently, and no; it's not cancer. It's fatty liver disease, particularly Non-alcoholic Fatty Liver Disease, or NAFLD, regarded by many as the most common non-communicable liver disease worldwide. The disease is a silent killer that often goes undetected until late stages, for which there are no FDA-approved treatments. Biotechs focusing on innovative therapies for varying stages of NAFLD are receiving plenty of deserved media coverage. Hepatology leaders in recent headlines include Intercept Pharmaceuticals, (NASDAQ: ICPT), Cempra, Inc. (NASDAQ: CEMP), MediciNova, Inc. (NASDAQ: MNOV), Galectin Therapeutics (NASDAQ: GALT) and Lumena Pharmaceuticals, a company preparing to go public.
Cempra's Solithromycin Demonstrates Therapeutic Potential Beyond Anti-Bacterial Activity
GlobeNewswire - Thu Apr 03, 3:05PM CDT
Cempra, Inc. (Nasdaq:CEMP) today announced the presentation of a late-breaking abstract entitled "Anti-NASH Effects of Solithromycin in NASH-HCC Mouse Model," at 9:15 a.m. EDT, May 6, at Digestive Disease Week (DDW(R)) 2014 in Room S105A at McCormick Place in Chicago. The presentation will be included in the session entitled "Basic Late Breaking Abstract Session."
Tetraphase Antibiotic Nearing Key Tolerability Test
at The Street - Wed Apr 02, 7:00AM CDT
The lead-in phase of a phase III study will tell us a lot about whether Tetraphase's eravacycline antibiotic can be administered orally.
Cempra to Present Late-Breaker on Solithromycin Reducing Inflammation in an Animal Model for Cancer Chemotherapy-Induced Lung Injury
GlobeNewswire - Thu Mar 27, 7:14AM CDT
Study Suggests Clinical Uses of Solithromycin Beyond Bacterial Infections
Cempra, Inc. to Present at The 21st Annual Future Leaders in the Biotech Industry Conference and Needham & Co. 12th Annual Healthcare Conference
GlobeNewswire - Thu Mar 20, 3:12PM CDT
Cempra, Inc. (Nasdaq:CEMP) today announced that Prabhavathi Fernandes, Ph.D., chief executive officer of Cempra, will present at The 21 Annual Future Leaders in the Biotech Industry Conference at 11:30 a.m. EDT, Friday, March 28, at the Millennium Broadway Hotel & Conference Center in New York City and at the Needham & Co. 12 Annual Healthcare Conference at 12:50 p.m. EDT, Wednesday, April 9, at The Westin New York Grand Central in New York City. Dr. Fernandes will discuss the company's two differentiated antibiotics, solithromycin (CEM-101) for community-acquired bacterial pneumonia and TAKSTA (CEM-102 or fusidic acid) for the chronic, oral treatment of Gram-positive pathogens including methicillin-resistant S. aureus (MRSA) in prosthetic joint infections.
What Falling Estimates & Price Mean for Cempra (CEMP) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 14, 7:45AM CDT
Cempra has witnessed a significant price decline in the past four weeks. The reason is negative trend in earnings estimate revisions. The stock also has seen some pretty dismal trading lately.
Cempra, Inc. to Present at Barclays Capital 2014 Global Healthcare Conference and 26th Annual ROTH Conference
GlobeNewswire - Fri Mar 07, 2:58AM CST
Cempra, Inc. (Nasdaq:CEMP) today announced that Prabhavathi Fernandes, Ph.D., chief executive officer of Cempra, will present at the Barclays Capital 2014 Global Healthcare Conference at 3:45 p.m. EST, Wednesday, March 12, at the Loews Miami Hotel in Miami Beach, Fla. and at the 26 Annual ROTH Conference at 3:30 p.m. PST, Monday, March 10, at The Ritz Carlton in Laguna Niguel, Calif. Dr. Fernandes will discuss the company's two differentiated antibiotics, solithromycin (CEM-101) for community-acquired bacterial pneumonia and TAKSTA (CEM-102 or fusidic acid) for the chronic, oral treatment of Gram-positive pathogens including methicillin-resistant S. aureus (MRSA) in prosthetic joint infections.
Cempra (CEMP) Falls: Stock Plunges 12.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 03, 7:35AM CST
The shares of Cempra fell over 12% on the day. This breaks the recent trend of the company, as the stock is now trading within the volatile price range of $11.2 to $13.7 in the past one-month time frame. This pharmaceutical company has seen a flat track record when it comes to current year estimate revisions.
Nasdaq stocks posting largest percentage decreases
AP - Fri Feb 28, 5:03PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Cempra, Inc. Reports Fourth Quarter and Full Year 2013 Financial and Operating Results
GlobeNewswire - Thu Feb 27, 3:14PM CST
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today reported financial results for the fourth quarter and full year ended Dec. 31, 2013. The company will host a conference call and webcast at 4:30 p.m. EST, today.
Report Reveals Wide Gap Between Successful and Struggling Communities, Reshaping American Landscape
PR Newswire - Wed Feb 26, 7:30AM CST
According to a comprehensive new report, there is a startling contrast in economic prosperity between successful and struggling American communities. America is divided into nine different community profiles, ranging from the successful -- the "Affluent Metroburbs" -- to the genuinely troubled -- the "Endangered Communities." Fifty percent of the American communities studied are struggling to find their way forward after the Great Recession.
Diabetic Gastroparesis - Pipeline Review, H1 2014 Research Report
M2 - Mon Feb 24, 3:19AM CST
Research and Markets (http://www.researchandmarkets.com/research/7ctztm/diabetic) has announced the addition of the "Diabetic Gastroparesis - Pipeline Review, H1 2014" report to their offering. 'Diabetic Gastroparesis - Pipeline Review, H1 2014', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Diabetic Gastroparesis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Diabetic Gastroparesis. Scope - A snapshot of the global therapeutic scenario for Diabetic Gastroparesis. - A review of the Diabetic Gastroparesis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Diabetic Gastroparesis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction Diabetic Gastroparesis Overview Therapeutics Development Late Stage Products Clinical Stage Products Early Stage Products Unknown Stage Products Assessment by Monotherapy Products Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Assessment by Therapeutic Class Drug Profiles metoclopramide hydrochloride - Drug Profile RM-131 - Drug Profile velusetrag - Drug Profile Non-Antibiotic Macrolide Program for Gastric Disorders - Drug Profile TC-6499 - Drug Profile Featured News & Press Releases Appendix List of Tables List of Figures Companies Mentioned Theravance, Inc. Evoke Pharma, Inc. Targacept, Inc. Cempra, Inc. Rhythm Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/7ctztm/diabetic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Cempra (CEMP) Jumps: Stock Adds 6.1% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 21, 8:39AM CST
Cempra, Inc. was a big mover last session, as its shares rose just over 6% on the day.
Cempra, Inc. to Report Fourth Quarter and Full Year 2013 Financial and Operating Results, and Host Conference Call and Webcast on Feb. 27, 2014
GlobeNewswire - Thu Feb 20, 3:20PM CST
Cempra, Inc. (Nasdaq:CEMP) today announced that it will report fourth quarter and full year 2013 financial results and provide a business update after the close of U.S. financial markets on Feb. 27, 2014. Prabhavathi Fernandes, Ph.D., president and chief executive officer of Cempra will host a conference call and webcast at 4:30 p.m. EST, Feb. 27, 2014.
Cempra Initiates Solithromycin Pediatric Program
GlobeNewswire - Thu Feb 20, 6:00AM CST
Cempra, Inc. (Nasdaq:CEMP) today announced the dosing of the first patient in its Phase 1 study of solithromycin capsules in children. The clinical trial is funded through Cempra's contract with the Biomedical Advanced Research and Development Authority (BARDA; http://www.phe.gov/about/barda/Pages/default.aspx).
Cempra, Inc. to Present at RBC Capital Markets 2014 Global Healthcare Conference and Cowen 34th Annual Health Care Conference
GlobeNewswire - Wed Feb 19, 3:05PM CST
Cempra, Inc. (Nasdaq:CEMP) today announced that Prabhavathi Fernandes, Ph.D., chief executive officer of Cempra, will present at the RBC Capital Markets 2014 Global Healthcare Conference at 1:35 p.m. EST, Tuesday, Feb. 25, at The New York Palace Hotel in New York City, and at the Cowen 34 Annual Health Care Conference at 1:30 p.m. EST, Monday, March 3, at The Boston Marriott Copley Place in Boston. Dr. Fernandes will discuss the company's two differentiated antibiotics, solithromycin (CEM-101) for community-acquired bacterial pneumonia and TAKSTA (CEM-102 or fusidic acid) for the chronic, oral treatment of Gram-positive pathogens including methicillin-resistant S. aureus (MRSA) in prosthetic joint infections.
Cempra (CEMP) Catches Eye: Stock Rises 9.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 12, 8:46AM CST
Cempra was a big mover last session, with shares rising nearly 10%.
Sensors Market in Consumer Electronics by Product, Application, & Geography - Worldwide Market Forecasts and Analysis to 2020
PR Newswire - Wed Feb 12, 6:22AM CST
Research and Markets
Cempra Antibiotic Candidate Clears Important Heart Safety Hurdle
at The Street - Tue Feb 11, 10:29AM CST
Cempra's solithromycin may have an important safety advantage over competing compounds.
